RAMAT GAN, Israel, Nov. 29, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reported today that the last healthy volunteer in its first ever safety study of cannabis-based topical ointment, was recently admitted in trial which is being conducted at Sheba Medical Center, Tel Hashomer, Israel. Mr. Mordechai Bignitz, OWC Pharmaceutical CEO commented: " We are extremely pleased with the progress on this trial. Recruiting has now been completed and we expect to complete the trial by the end of December".
Mr. Bignitz added: "We recently had the opportunity to present our innovative research and pipeline progress to investors and potential business partners at the MJBizCon in Las Vegas. We are evaluating a number of potential avenues to accelerate our development as we strongly believe that our innovative dosage forms, delivery platforms and our clinical research can unlock the potential of cannabis-based treatments and improve patients'quality of life".
About OWC Pharmaceutical Research Corp
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
OWCP is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.
Contact: Mordechai Bignitz , Chief Executive Officer - OWC Pharmaceutical research crop,
email@example.com, Tel: +972-(72)-260-8004
SOURCE OWC Pharmaceutical Research Corp.